Expression of long non-coding RNA ANRIL predicts a poor prognosis in intrahepatic cholangiocarcinoma

Angenard, Gaëlle; Merdrignac, Aude; Louis, Corentin; Edeline, Julien; Coulouarn, Cédric

doi:10.1016/j.dld.2019.03.019

Cited by 34 publications

(25 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 8 Even, one kind of long noncoding RNA may be a prognosis biomarker in several tumors concurrently, such as CDKN2B-AS1 (ANRIL) which is a poor prognosis biomarker in intrahepatic cholangiocarcinoma, hepatocellular carcinoma, or uterine corpus endometrial carcinoma. 9 LINC00460 was reported to be associated with poor prognosis of several cancers, such as lung squamous cell carcinoma, 10 colorectal cancer, 11 breast cancer. 12 LINC00460 has been screened to be associated with the overall survival of ccRCC patients, but its prognostic value and effect on cellular function in ccRCC have not been studied.…”

Section: Introductionmentioning

confidence: 99%

Aberration of lncRNA LINC00460 is a Promising Prognosis Factor and Associated with Progression of Clear Cell Renal Cell Carcinoma

Zhang¹,

Zhang²,

Niu³

et al. 2021

CMAR

View full text Add to dashboard Cite

Purpose Long noncoding RNAs have been studied more and more as potential prognostic markers. However, the prognostic of LINC00460 in clear cell renal cell carcinoma (ccRCC) has not been explored. In this study, the potential role of LINC00460 was investigated in ccRCC. Patients and Methods One hundred thirteen pairs of ccRCC tissues and para-normal tissues were collected. The expressions of LINC00460 in these tissues and ccRCC cells were evaluated via qRT-PCR. The prognostic value of LINC00460 was accessed with the use of Kaplan–Meier analysis and Cox proportional hazards model analysis. The influence of LINC00460 on ccRCC cell proliferation, migration, and invasion was determined via cell counting kit-8 (CCK-8) and Transwell assays. Results The results revealed that LINC00460 was significantly enhanced in ccRCC tissues, as well as in ccRCC cell lines. The overexpression of LINC00460 was significantly associated with lymph node metastasis and TNM stage, and lead to poor overall survival. Knockdown of LINC00460 reduces the cell ability of proliferation, migration, and invasion. LINC00460 could sponge to miR-149-5p. Conclusion LINC00460 may be developed as a prognostic biomarker and molecular therapy target for ccRCC.

show abstract

Section: Introductionmentioning

confidence: 99%

Aberration of lncRNA LINC00460 is a Promising Prognosis Factor and Associated with Progression of Clear Cell Renal Cell Carcinoma

Zhang¹,

Zhang²,

Niu³

et al. 2021

CMAR

View full text Add to dashboard Cite

show abstract

“…Traditionally, as a systematic anatomic-based classification, the TNM stage provides a method to estimate cancer prognosis (Huang and O'Sullivan, 2017). Recently, with the development of precision medicine, accumulating evidence demonstrated that lncRNAs possess a potential predictive value in cancer prognosis (Angenard et al, 2019;Li et al, 2019;Xu et al, 2019). Thus, it was shown that the prognostic model generated by combining lncRNAs with TNM stage provides higher predictive ability compared to currently available prognostic systems.…”

Section: Discussionmentioning

confidence: 99%

Integrated Analysis of lncRNA-Mediated ceRNA Network Reveals a Prognostic Signature for Hepatocellular Carcinoma

Sun¹,

Kong²,

Xiao³

et al. 2020

Front. Genet.

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most common types of malignancy and is associated with high mortality. Prior research suggests that long non-coding RNAs (lncRNAs) play a crucial role in the development of HCC. Therefore, it is necessary to identify lncRNA-associated therapeutic biomarkers to improve the accuracy of HCC prognosis. Transcriptomic data of HCC obtained from The Cancer Genome Atlas (TCGA) database were used in the present study. Differentially expressed RNAs (DERNAs), including 74 lncRNAs, 16 miRNAs, and 35 mRNAs, were identified using bioinformatics analysis. The DERNAs were subsequently used to reconstruct a competing endogenous RNA (ceRNA) network. A lncRNA signature was revealed using Cox regression analysis, including LINC00200, MIR137HG, LINC00462, AP002478.1, and HTR2A-AS1. Kaplan-Meier plot demonstrated that the lncRNA signature is highly accurate in discriminating high- and low-risk patients (P < 0.05). The area under curve (AUC) value exceeded 0.7 in both training and validation cohort, suggesting a high prognostic potential of the signature. Furthermore, multivariate Cox regression analysis indicated that both the TNM stage and the lncRNA signature could serve as independent prognostic factors for HCC (P < 0.05). Then, a nomogram comprising the TNM stage and the lncRNA signature was determined to raise the accuracy in predicting the survival of HCC patients. In the present study, we have introduced a ceRNA network that could contribute to provide a new insight into the identification of potential regulation mechanisms for the development of HCC. The five-lncRNA signature could serve as a reliable biosignature for HCC prognosis, while the nomogram possesses strong potential in clinical applications.

show abstract

“…This mechanism has been confirmed in multiple gastrointestinal cancers but not in cholangiocarcinoma [42]. However, lncRNAs such as PVT1 [43], UCA1 [44], and ANRIL [45], which have been verified to be induced by hypoxia in gastrointestinal cancers [41,42], were also abnormally expressed in CCA, suggesting that further exploration of hypoxia-regulated lncR-NAs in CCA should be carried out.…”

Section: Regulators Of Lncrnas In Ccamentioning

confidence: 93%

Emerging roles of long noncoding RNAs in cholangiocarcinoma: Advances and challenges

Yang

Deng

et al. 2020

Cancer Communications

View full text Add to dashboard Cite

Cholangiocarcinoma (CCA), a cancer with a relatively low incidence rate, is usually associated with poor prognosis. Current modalities for the diagnosis and treatment of CCA patients are still far from satisfactory. In recent years, numerous long noncoding RNAs (lncRNAs) have been identified as crucial players in the development of various cancers, including CCA. Abnormally expressed lncRNAs in CCA, regulated by some upstream molecules, significantly influence the biological behavior of tumor cells and are involved in tumor development through various mechanisms, including interactions with functional proteins, participation in competing for endogenous RNA (ceRNA) regulatory networks, activation of cancer‐related signaling pathways and epigenetic modification of gene expression. Furthermore, several lncRNAs are closely associated with the clinicopathological features of CCA patients, and are promising biomarkers for diagnosing and prognostication of CCA. Some of these lncRNAs play an important role in chemotherapy drug resistance. In addition, lncRNAs have also been shown to be involved in the inflammation microenvironment of CCA and malignant outcome of CCA risk factors, such as cholestatic liver diseases. In view of the difficulty of diagnosing CCA, more attention should be paid to detectable lncRNAs in the serum or bile. This review summarizes the recent knowledge on lncRNAs in CCA and provides a new outlook on the molecular mechanisms of CCA development from the perspective of lncRNAs. Moreover, we also discussed the limitations of the current studies and differential expression of lncRNAs in different types of CCA.

show abstract

Expression of long non-coding RNA ANRIL predicts a poor prognosis in intrahepatic cholangiocarcinoma

Cited by 34 publications

References 52 publications

Aberration of lncRNA LINC00460 is a Promising Prognosis Factor and Associated with Progression of Clear Cell Renal Cell Carcinoma

Aberration of lncRNA LINC00460 is a Promising Prognosis Factor and Associated with Progression of Clear Cell Renal Cell Carcinoma

Integrated Analysis of lncRNA-Mediated ceRNA Network Reveals a Prognostic Signature for Hepatocellular Carcinoma

Emerging roles of long noncoding RNAs in cholangiocarcinoma: Advances and challenges

Contact Info

Product

Resources

About